D.E. Shaw & Co’s Ibere Pharmaceuticals IBER Stock Holding History

D.E. Shaw & Co’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-150,000	Closed	-$1.51M	–	5152
2022 Q4	$1.51M	Sell	150,000 -125,008	-45%	-$1.25M	﹤0.01%	3155
2022 Q3	$2.73M	Buy	275,008 +100	+0%	+$986	﹤0.01%	2725
2022 Q2	$2.7M	Buy	274,908 +101,946	+59%	+$1,000K	﹤0.01%	2806
2022 Q1	$1.7M	Sell	172,962 -231,214	-57%	-$2.25M	﹤0.01%	3467
2021 Q4	$3.93M	Buy	404,176 +242,637	+150%	+$2.36M	﹤0.01%	2653
2021 Q3	$1.56M	Buy	161,539 +136,539	+546%	+$1.32M	﹤0.01%	3237
2021 Q2	$242K	Buy	+25,000	New	+$243K	﹤0.01%	4378

D.E. Shaw & Co's IBER Position: Q1 2023 in Review

D.E. Shaw & Co sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 150,000 shares — an estimated $1.51M sold.

D.E. Shaw & Co first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $3.93M in Q4 2021. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

D.E. Shaw & Co reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
D.E. Shaw & Co sold 150,000 Ibere Pharmaceuticals shares in Q1 2023, an estimated $1.51M.
D.E. Shaw & Co first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
D.E. Shaw & Co's Ibere Pharmaceuticals position peaked at $3.93M in Q4 2021.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.